New research reveals a significant gap in statin eligibility for African Americans under different guidelines, highlighting the need for personalized treatment. The study found that stricter USPSTF guidelines may miss some individuals with vascular calcification and low or moderate risk.
The EBBINGHAUS study, the largest and most rigorous study on the topic, found no significant cognitive effects from adding evolocumab to statin therapy. The study enrolled 1,974 patients and used validated neurocognitive tests to assess executive function, working memory, and reaction time.
The new iFR tool has been shown to be equivalent to the current preferred tool FFR in terms of major adverse events and patient outcomes. It also resulted in markedly less patient discomfort and reduced procedure-related adverse events compared to FFR.
Researchers found that only 2% of PE patients receive advanced treatments, despite being potential candidates. The study highlights the need for better real-world data on these therapies to improve patient outcomes.
A study found that approximately 1 in 4 African American individuals recommended for statin therapy under ACC/AHA guidelines are no longer eligible under USPSTF guidelines. This disparity highlights the need to personalize statin recommendation, leveraging targeted imaging measures.
A study of 18 ACL patients found that higher levels of collagen breakdown at the time of surgery correlate with worse outcomes two years after. This suggests that initial biochemical changes after injury may have a lasting impact on osteoarthritis development.
Participants in an online behavioral intervention for high blood pressure reduced their systolic blood pressure by 10 mmHg, compared to a 6 mmHg reduction for those taking part in a control group. The study found that lifestyle counseling can complement and optimize the effectiveness of medical therapy to reduce high blood pressure.
A large international study found that rivaroxaban is more effective and safer than aspirin at preventing recurrent blood clots. The study showed that patients taking rivaroxaban had significantly lower rates of recurrent clots compared to those taking aspirin.
A Phase 2 trial found that synthetic high-density lipoprotein cholesterol (HDL-C) injections had no effect on reducing fatty deposits in arteries, despite being well-tolerated. The study's findings suggest that low-dose CER-001 may not be a promising agent for treating patients with acute coronary syndrome.
A new study published by the American College of Cardiology found that percutaneous coronary intervention (PCI) is not needed in all cases of fully blocked arteries. Treatment with medications alone was shown to be equal to PCI in terms of major adverse events over three years.
A Phase 2 study found that replacing aspirin with low-dose rivaroxaban in addition to an antiplatelet medication does not increase bleeding complications in patients with acute coronary syndrome. The study, which involved over 3,000 patients, suggests that this dual therapy approach may be a safe alternative to lifelong aspirin treatment.
A recent study suggests that surgical approaches to treating tennis elbow may not provide additional benefits compared to a placebo procedure. Patients who underwent surgery experienced significant improvements in pain measures within 26 weeks, with no significant difference between the two groups at any point.
Patients receiving Absorb stent showed outcomes similar to those of Xience metal stents between years one and two, but elevated risk of adverse outcomes at two years in smaller vessels. The study highlights the importance of using appropriately sized vessels and refined procedural techniques for optimal results.
A study of 13,089 patients found that higher physical therapy utilization after ACL reconstruction increases the risk of a second ACL injury. Young female athletes are at particular risk.
New research shows that evolocumab, a PCSK9 inhibitor, effectively lowers LDL cholesterol levels beyond current targets and reduces adverse cardiovascular events. In contrast to previous studies, this study found no association between evolocumab use and decline in memory or cognitive function.
A low-dose blood-thinning medication reduced VTE recurrences more than threefold compared to aspirin without increasing bleeding side effects, according to a large international study. The study's findings support the use of rivaroxaban as a safe and effective treatment option for patients at risk for recurrent VTE.
Researchers combined two independent risk measurements to improve stroke and mortality predictions in atrial fibrillation patients. The new tool provides a more accurate scale of low and high risk, helping physicians determine the need for blood thinners in treatment.
Researchers at Intermountain Medical Center Heart Institute have identified three microRNA molecules linked to AFib recurrence after ablation therapy. These molecular markers hold promise as screening tools to help determine which patients will benefit from various therapies.
Professional baseball players face low success rates after undergoing biceps tenodesis surgery, with only 35% returning to pre-operative levels. Ability to recover varies by position, with pitchers showing less success compared to other players, according to research.
A study by researchers found that schools using a Heads Up tackling education program experienced a 1.4 times lower risk of concussions in high school football athletes compared to those without training. The program also led to faster returns to play, with the Heads Up group returning to play 27% faster than non-Heads Up teams.
A study found that arthroscopic superior capsule reconstruction significantly improves shoulder function and stability in patients with rotator cuff tears. The surgical approach eliminated pseudoparalysis in 96.3% of moderate and 93.3% of severe cases.
A new study by Intermountain Medical Center Heart Institute researchers suggests that calcified plaque is associated with a higher risk of cardiovascular events, contradicting previous assumptions about soft plaque. The study found that patients with more calcified plaque were more likely to experience major adverse coronary events.
Researchers found that treating secondary blockages after a major heart attack using fractional flow reserve technology can improve patient outcomes and reduce the need for subsequent invasive procedures. This approach resulted in a 65% lower risk of all-cause mortality, non-fatal heart attack, stroke, and revascularization at 12 months.